Moleculera Biosciences’ cover photo
Moleculera Biosciences

Moleculera Biosciences

Biotechnology

Oklahoma City, Oklahoma 976 followers

A Precision Medicine Company.

About us

Moleculera Biosciences is a precision medicine company focused on identifying and directing treatment for immune-mediated causes of chronic debilitating disorders. Through our fully-accredited CLIA/COLA clinical laboratory, we specialize in molecular diagnostic testing for autoimmune neuroimmunology. As pioneers focusing on neuropsychiatric disorders caused by molecular mimicry, we offer the Autoimmune Brain Panel™, an aid to a physician’s diagnosis of autoimmune-based neuropsychiatric disorders. The Autoimmune Brain Panel™ helps identify whether an individual’s neurologic/psychiatric symptoms, such as obsessive compulsive behaviors, tics, anxiety, attention deficit hyperactivity disorder, and sometimes behaviors associated with Autism Spectrum Disorders, could be caused by a treatable autoimmune condition triggered by common infections.

Website
http://www.moleculera.com
Industry
Biotechnology
Company size
11-50 employees
Headquarters
Oklahoma City, Oklahoma
Type
Privately Held
Founded
2011
Specialties
Immunology, Lyme Disease, Autoimmune Encephalopathy, PANDAS/PANS, and Neuropsychiatric Illness

Locations

  • Primary

    755 Research Pkwy

    Suite 410

    Oklahoma City, Oklahoma 73104, US

    Get directions

Employees at Moleculera Biosciences

Updates

  • Moleculera Biosciences reposted this

    Join us at Bio this year to hear about the growing ecosystem in Life Sciences in Oklahoma! Excited about the conversation and the group of panelists that will be representing Oklahoma this year!

    View organization page for Wheeler Bio, Inc.

    6,977 followers

    On June 22, Wheeler Bio’s CEO will be joining leaders from across the Oklahoma life science ecosystem at the Life Science Oklahoma networking breakfast in San Diego, an event dedicated to showcasing the momentum and innovation coming out of Oklahoma’s rapidly growing life sciences sector. As the global biotech community gathers for BIO 2026, bringing together thousands of industry leaders, innovators, and investors, this breakfast is an exciting opportunity to learn about Oklahoma City's rapidly growing biotech hub. We hope all our partners can join us for this special spotlight on all the benefits of building innovations in Oklahoma. #BIO2026 #LifeSciences #Biotech #Oklahoma #CDMO #Biologics #Innovation

    • No alternative text description for this image
  • Moleculera Biosciences reposted this

    Our CEO, Vicky Burford, and our Health and Policy Lead, Katy Hindson, travelled to the European Parliament in Brussels last week to speak at an event organised by Associazione Genitori PANS PANDAS BGE, the Italian equivalent of PANS PANDAS UK. They were joined by proud PANDAS parents Neil and Lucie Gilson (left) who shared their story, and ISCA Evidence teammates Dr Michael Nunns and Sam Febrey (right) who introduced PANS PANDAS unveiled. The event was attended by many PANS and PANDAS charities and organisations, including PANS+ Scotland. "Bringing together parliamentarians, clinicians, scientists, patient organisations and families, this important event clearly demonstrated the depth of need for increased awareness and support, and the importance of working collaboratively to meet this need." - Katy Hindson, our Health and Policy Lead. To learn more, and watch all the presentations, visit: https://lnkd.in/eKn7a6Dh

    • No alternative text description for this image
  • Moleculera Biosciences reposted this

    Before a psychiatric diagnosis can be made, it has to survive a medical workup. This is one of the most important, and most consistently missed, steps in mental health care. The brain runs on glucose, oxygen, hormones, nutrients, and an immune system it shares with every other organ. When any of those inputs are disrupted, the brain produces symptoms indistinguishable from psychiatric illness. Examples of what gets missed every day: ⚕️ Hypothyroidism can present as depression. Studies show up to 26.2% of depressed patients have abnormal thyroid function. Treating the thyroid condition should be the first step. ⚕️ Hyperthyroidism can look like anxiety or mania: racing thoughts, insomnia, irritability, and palpitations mimicking panic disorder or hypomania. ⚕️ Iron deficiency can mimic ADHD or depression. Iron is important in dopamine synthesis, and testing without ferritin levels routinely misses this etiology. ⚕️ B12 deficiency can manifest as depression, cognitive decline, and in severe cases psychosis. Neurological impairment can occur at levels considered normal by standard reference ranges. ⚕️ Sleep apnea can present as depression and ADHD: cognitive fog and low energy are driven by chronic hypoxia and fragmented sleep. ⚕️ POTS and dysautonomia can look like anxiety, depression, and cognitive dysfunction, driven by cerebral hypoperfusion when upright, not primary psychiatric illness. ⚕️ PANDAS/PANS manifests as sudden-onset OCD, tics, anxiety, and behavioral change in children. The hallmark is dramatic onset, often overnight, following streptococcal or other infection. ⚕️ Autoimmune encephalitis can present as psychosis. 75% of anti-NMDA receptor encephalitis patients first present to a psychiatrist. It is treatable, but can be fatal when missed. ⚕️ Cushing's disease can look like bipolar disorder: cortisol excess produces mood instability, insomnia, and cognitive impairment. Here's what a basic workup for any psychiatric condition should include: → CBC, CMP, TSH, free T4, B12, folate, vitamin D, iron studies with ferritin, fasting glucose, HbA1c, lipid panel, CRP, urinalysis, toxicology screen. Suspected POTS: → Orthostatic vitals (supine, sitting, standing at 1, 3, and 10 minutes); tilt table test if indicated. Suspected PANDAS/PANS: → Throat culture, rapid strep, ASO titer, anti-DNase B antibody, CBC with differential, ANA, ESR, CRP, mycoplasma IgM/IgG. First-episode psychosis: → Add ANA, anti-NMDA antibodies, HIV, RPR, neuroimaging. Treating a medical condition as a psychiatric one can cost years of a patient's life. The most evidence-based first step in mental health care is ruling out the medical conditions that produce psychiatric symptoms. We should be doing it every time. Follow me Britton Ashley Arey, MD MBA for evidence-based perspectives on psychiatry, mental health, and the science of the mind. #Psychiatry #MentalHealth #IntegratedCare #MindBodyMedicine #MentalHealthAwarenessMonth

    • No alternative text description for this image
  • Moleculera Biosciences reposted this

    Before assigning a psychiatric diagnosis, rule out medical causes first. As part of ASPIRE’s 10-day series for Mental Health Awareness Month, we’re bringing awareness and understanding to PANS/PANDAS. This isn’t controversial — it’s standard clinical guidance. PANS/PANDAS is one of the conditions that should be considered. Missing this step delays care and changes outcomes.

    • No alternative text description for this image
  • Moleculera Biosciences reposted this

    Not every tick bite comes with a bullseye rash. Lyme disease can go unnoticed and, if left untreated, may trigger neuroinflammation linked to PANS/PANDAS. For many families, the first signs are sudden behavioral or neurological changes not a clear infection. This Lyme Disease Awareness Month, we’re reminding you to look beyond the obvious. Know the symptoms. Trust what you’re seeing. Early intervention can change everything. #LymeDiseaseAwareness #PANS #PANDAS #Neuroinflammation #TickBorneIllness #LookForRootCauses #MentalHealthAwareness #ChronicIllness #LookFoundation

    • No alternative text description for this image
  • Moleculera Biosciences reposted this

    🧠 𝗦𝗔𝗩𝗘 𝗧𝗛𝗘 𝗗𝗔𝗧𝗘 Siamo lieti di annunciare il Webinar: “𝗟𝗮 𝗻𝗲𝘂𝗿𝗼𝗶𝗺𝗺𝘂𝗻𝗼𝗺𝗼𝗱𝘂𝗹𝗮𝘇𝗶𝗼𝗻𝗲 𝗻𝗲𝗹𝗹𝗮 𝗣𝗔𝗡𝗦” 📅 3 giugno 2026 ⏰ Ore 20:00 – 22:00 Un momento di approfondimento scientifico dedicato al rapporto tra sistema immunitario, neuroinfiammazione e sistema nervoso nella Sindrome PANS. L’incontro vedrà la partecipazione di: 🔹 Dott.ssa Augusta Rizzo – Neurologa Pediatra 🔹 Prof. Alessio Filippo Peritore – Professore Associato di Farmacologia L’evento è promosso da PANS PANDAS Italia APS con il patrocinio di UNIAMO Federazione Italiana Malattie Rare e con il contributo non condizionante di Epitech Group SpA. Il webinar sarà rivolto a famiglie, professionisti della salute e a tutti gli interessati ad approfondire i meccanismi neuroimmunologici coinvolti nella PANS. Modalità di partecipazione. 🌐 https://lnkd.in/dSuvaGnj #PANS #PANDAS #Neuroinfiammazione #Neuroimmunologia #MalattieRare #Ricerca #UNIAMO #EPITECHGROUP

    • No alternative text description for this image
  • Moleculera Biosciences reposted this

    Agree. Where is the accountability? Children and families have been medically abandoned for decades in autism, PANS/PANDAS, and Lyme. Upstream treatable causes are proven yet ignored. The NIH had a $48B publicly-funded budget in 2025, but zero clinical trials targeted upstream causes of brain disorders. Instead, billions flowed into amyloid‑removal strategies that failed, as shown in the 2025 Cochrane meta‑analysis of 20,432 participants. Academic centers remain locked into downstream research because that is where drug‑company‑funded trials occur—only when profitable. Who were the leaders at the APA, AAP, AAN, AMA, ANA, NIH, HHS, and IDSA? Some knew the data, especially in Lyme, autism, and PANS/PANDAS. Can they be held accountable? Why are drug companies leading clinical trials at all? They could simply bid to supply medications. Low‑cost treatments never advance. The B12 documentary shows how B12 deficiency has been known to cause brain disorders since Pacholok’s 2005 book—yet was ignored because B12 is inexpensive and unprofitable. MTHFR variants reduce the ability to convert B12 into neurotransmitters, requiring different forms of B12 in many with mental illness and autism. Where were our leaders? In 2025, MDs and DOs led the EVANTHEA trial, reversing dementia in nine months using decentralized, multimodal, UPSTREAM testing and treatment. This model works—even in autism. It should be replicated across all brain disorders, where causes include infections, toxins, and nutrient deficiencies. COPY IT for all brain patients! 2026 "Patient Right to Ethical Treatment" needs to require tests of proven treatable causes before drugs or research treatments as a priority for all advocacy organizations. DNA SNPs resource: https://lnkd.in/eqsEQaS5 B12 documentary: https://lnkd.in/eQchtmzi For‑profit incentives shape research, education, CME, medical schools, clinics, and hospitals. Patients pay the price. If you want, I can create a more forceful version, a policy‑brief version, or a version tailored for clinicians vs. lawmakers.

    We are witnessing the consequences of using the wrong language and old notions of what "mental" illness really is--neurological, biological malfunctions of the brain--in our systemic failures to medically treat and manage these treatable brain diseases. We see the results on our streets, in our courts, in our carceral systems, and too often in our morgues, every day. Suffering people who, with the right care, at the right time, in the right place with supportive services, can live their best lives in a state of stability and recovery. Their human right to restorative healthcare is being denied due to the nature and misunderstanding about their medical illness. It's way past time to regroup, attach the brain back onto the body, and treat these conditions medically like any other organ-based diseases. We are destroying families and very sick folks who have the right to be well. No other diseases are being denied medical treatment due to the nature of their illness. This is neglect, an abdication of authority, and just plain wrong and inhumane. #schizophrenia #bipolardisorders #psychosis #anosognosia #discrimination

  • Moleculera Biosciences reposted this

    In this clip from our recent interview at ILADS, Michael Cook BSc, Independent Lyme disease Researcher discusses his perspective on the scale of Lyme disease in the UK and reflects on the importance of learning from the experiences of those affected. Tonight, Michael joins Kirstie Haysman and Sarah Grace for From Challenge to Change: Voices of Lyme & Lived Experience, a webinar centred around the realities of living with Lyme disease, the challenges patients face, and the power of shared experiences. As part of Lyme Disease Awareness Month, this session aims to create a safe and supportive space for patients, families, and anyone navigating Lyme to feel informed, understood, and less alone. There’s still time to register your place here: https://lnkd.in/etSsNk9k 🗓 Tuesday 12th May 🕖 7PM BST | 8PM CEST | 2PM EDT

  • Moleculera Biosciences reposted this

    At the lowest point in my chronic illness, one study changed my entire trajectory. At the time, I was navigating multiple diagnoses, including interstitial cystitis and severe refractory asthma. While these were being treated as separate conditions, the research I came across suggested there may be underlying connections – particularly the potential role of infection. This blew my mind and reframed how I previously understood my illness and autoimmunity. This ultimately informed life-saving care that followed. Today, that experience drives and inspires my work. I collaborate with researchers and clinicians to better understand how infections may contribute to chronic, multi-system illness. We built a rigorous, multidisciplinary research framework to study a big question - Which infections may drive chronic disease and how are they doing it? By bridging research silos that do not normally cross-pollinate, some of the brightest minds in the field are converging. Here’s the big takeaway 👇 To my fellow chronic illness patients: Keep asking questions. You know your body better than anyone. To clinicians/researchers: consider infectious root-causes – the evidence is too compelling to ignore.

  • A new study highlights two patients with new-onset, treatment-resistant seizures associated with Lyme disease. In one case, a 14-year-old girl developed treatment-resistant myoclonic seizures and subsequently tested positive for Lyme disease. Given concern for an immune-mediated process, she underwent testing with the Autoimmune Brain Panel™ (formerly the Cunningham Panel™), which identified evidence of an underlying autoimmune process potentially driving her symptoms. Following treatment with steroids, IVIG, and antibiotics, the patient experienced a complete resolution of seizures and was able to discontinue anti-seizure medication. "These findings underscore the importance of considering infection-triggered immune dysfunction in patients with sudden-onset neuropsychiatric or neurological symptoms that do not respond to standard therapies," the authors suggest. #lymedisease #neuropsychiatric #seizures https://lnkd.in/gNdtAR7r

Similar pages

Browse jobs